Zimbabwe has declined a major US health deal worth $367m (£272m) spanning five years due to the United States' request for confidential biological samples.
The decision became public after a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesman has since stated that the US was requesting biological samples for research and commercial purposes while was unwilling to guarantee the benefits from future vaccines.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had provided over $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has urged continued talks to find a agreement agreeable to both sides so the country's vital HIV programme can continue.
Wider Background
This development comes after a comparable case in neighbouring Kenya, where a court halted a related deal with the US following legal challenges were filed about the security of citizens' medical information.
Since returning to the presidency last year, US President Donald Trump has reduced foreign aid and shut down the key foreign aid agency.
USAID had overseen assistance for the American government, but Trump stated its expenditure was "wasteful" and his government was seeking government-to-government deals to boost openness and accountability.
As per statements, Sixteen African countries have so far signed these new health pacts, constituting over $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We believe this collaboration might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no equivalent promise of benefiting from any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Put simply, our country would supply the basic resources for scientific discovery with no certainty that the final treatments would be available to our citizens should a future health crisis emerge."
National Interest and Global Health
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were disrupting structures previously set up via the global health agency.
The spokesperson cited its Pandemic Benefit-Sharing system created to manage future global health emergencies.
"This mechanism is designed to guarantee that when a country provides its data, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage further dialogue with our US partners on how future co-operation could be arranged in a manner that honours the sovereignty and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it acknowledged the government's concerns, but suggested that negotiations should continue given that much of the country's Aids initiatives were funded by international support.
"In cases where specific concerns arise, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," the group said.
The situation emphasises the ongoing tensions between accepting crucial international aid and protecting local interests in an increasingly data-driven world.